Cerenome (CNSY)

Its lead programme is rhenium (186Re) obisbemeda, a radiotherapeutic candidate designed to concentrate radiation in cancerous tissue while limiting exposure to surrounding healthy structures. Plus Therapeutics is evaluating this asset in indications including recurrent glioblastoma and leptomeningeal metastases, two aggressive conditions where existing therapies often provide only modest benefit. The same platform is also being explored for paediatric brain cancers, reflecting the company’s broader focus on rare and high-need oncology settings.

The company’s strategy combines drug development with specialised delivery approaches, since central nervous system tumours can be difficult to reach through conventional systemic therapy. By using local or targeted administration, Plus Therapeutics aims to improve the therapeutic index of radiation-based treatment in areas where surgery, external beam radiation, and chemotherapy may be inadequate.

As a Nasdaq-listed development-stage company, Plus Therapeutics is primarily valued by investors on clinical progress, regulatory milestones, financing capacity, and the commercial potential of its pipeline. Its shares tend to reflect the higher-risk profile common to small biotechnology businesses, where trial outcomes and funding needs can materially affect market expectations.